<DOC>
	<DOCNO>NCT01617928</DOCNO>
	<brief_summary>This Phase 1 open-label study consist 3 treatment group ( dose level ) . Treatment cycle 3 week duration . The primary objective study determine recommend phase two dose ( RPTD ) veliparib ( ABT-888 ) administer combination carboplatin paclitaxel Japanese subject solid tumor . Secondary objective assess pharmacokinetics obtain preliminary efficacy anti-tumor activity subject .</brief_summary>
	<brief_title>A Study Veliparib Combination With Carboplatin Paclitaxel Japanese Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients must histologically cytologically confirm malignant solid tumor . Patients amenable standard combination chemotherapy carboplatin paclitaxel . Patients receive less equal 1 prior chemotherapy regimen advance stage disease . Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 . Patients must normal organ marrow function Patients chemotherapy radiotherapy within 3 week ( 6 week nitrosoureas mitomycin C ) prior enter study adverse event due agent administer 3 week earlier recover less grade 2 . Known history allergic reaction carboplatin cremophorpaclitaxel . Patients previously receive poly ( ADPribose ) polymerase ( PARP ) inhibitor . Uncontrolled intercurrent illness include , limited , ongoing active systemic infection require treatment , symptomatic congestive heart failure , angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . History seizure disorder . Hepatitis B surface antigen ( HBsAg ) positive , Hepatitis C virus ( HCV ) antibody positive Human immunodeficiency virus ( HIV ) positive patient .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>